The Stroke Prevention by Aggressive Reduction in Cholesterol Levels ( SPARCL ) trial assessed the effect of statin treatment on the risk of nonfatal and fatal stroke in subjects with a noncardioembolic stroke or transient ischemic attack , no known coronary heart disease , and low-density lipoprotein cholesterol between 2.6 and 4.9 mmol/L ( 100-190 mg/dL ) .